Prioritizing Gene Cascading Paths to Model Colorectal Cancer Through Engineered Organoids

Abstract

Engineered organoids by sequential introduction of key mutations could help modeling the dynamic cancer progression. However, it remains difficult to determine gene paths which were sufficient to capture cancer behaviors and to broadly explain cancer mechanisms. Here, as a case study of colorectal cancer (CRC), functional and dynamic characterizations of five types of engineered organoids with different mutation combinations of five driver genes (APC, SMAD4, KRAS, TP53, and PIK3CA) showed that sequential introductions of all five driver mutations could induce enhanced activation of more hallmark signatures, tending to cancer. Comparative analysis of engineered organoids and corresponding CRC tissues revealed sequential introduction of key mutations could continually shorten the biological distance from engineered organoids to CRC tissues. Nevertheless, there still existed substantial biological gaps between the engineered organoid even with five key mutations and CRC samples. Thus, we proposed an integrative strategy to prioritize gene cascading paths for shrinking biological gaps between engineered organoids and CRC tissues. Our results not only recapitulated the well-known adenoma-carcinoma sequence model (e.g., AKST-organoid with driver mutations in APC, KRAS, SMAD4, and TP53), but also provided potential paths for delineating alternative pathogenesis underlying CRC populations (e.g., A-organoid with APC mutation). Our strategy also can be applied to both organoids with more mutations and other cancers, which can improve and innovate mechanism across cancer patients for drug design and cancer therapy.

P2RY13 is a prognostic biomarker and associated with immune infiltrates in renal clear cell carcinoma: A comprehensive bioinformatic study

“…Because it modifies cytokine interactions to govern cancer growth and progression, cytokine-cytokine receptor interaction is a crucial immunological signaling mechanism 76 ; inflammation, tumor immunology, and tumor metastasis are all influenced by cytokine-receptor interactions. 77,78 Immunosuppression has also been linked to cytokine-cytokine receptor interactions. 79 The antitumor immunity of hosts consists of both innate and adaptive immune responses, but it is the adaptive immune system that is crucial for triggering powerful and highly targeted immune responses.…”

“…Significant enrichment pathways included actin filament organization, immune response activation, adaptive immune responses, cytokine receptor interactions, adhesion, and neuroactive ligand‐receptor interactions. Because it modifies cytokine interactions to govern cancer growth and progression, cytokine–cytokine receptor interaction is a crucial immunological signaling mechanism 76 ; inflammation, tumor immunology, and tumor metastasis are all influenced by cytokine–receptor interactions 77,78 . Immunosuppression has also been linked to cytokine–cytokine receptor interactions 79 .…”

Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges

“…Genetic alterations that are present in tumours are captured using tumouroids, and as such, they have been used to determine a patient’s progression of cancer and response to treatment [ 87 ]. As an example, in colorectal cancer, driver mutation genes such as APC, KRAS, TP53, SMAD4, Wnt, and PIK3CA can be found in colorectal tumouroids [ 88 ].…”

P53 Over Expression in Bladder Carcinoma

“…6 Many other cellular proteins, such as those involved in programmed cell death regulation, interact with p53, and these molecular interactions may contribute to p53's tumor-inhibiting activity. 8 Bladder urothelial carcinoma often has a mutant p53 gene. Mutations in the p53 gene result in a metabolically stable and long-lived protein.…”